Invitae

Medical device mergers on pause

2019 was an average year for medtech M&A. 2020, not so much.

Smaller device makers put in a muted performance

Mid- and small-cap medtechs find themselves at the mercy of government responses to the Covid-19 pandemic.

June 23, 2020

Invitae ends medtech merger drought with ArcherDX deal

The cash-and-stock deal, worth $886m up front, is the first major liquid biopsy acquisition since Roche bought Foundation Medicine.